Live attenuated Shigella strains developed so far are invasive and afford serotype-dependent protection. In contrast, the proprietary Eveliqure vaccine technology platform is based on a live, genetically attenuated Shigella vaccine strain able to induce broad protection against shigellosis.

​

The platform is amenable for the heterologous expression of diarrheal antigens and therefore can provide protective immunity against multiple pathogens. The first product candidate, ShigETEC expresses ETEC antigens known to induce protective immunity against ETEC infections when expressed in appropriate forms.

​

The vaccine will be administered orally in a liquid form, and expected to induce mucosal immune response that is necessary to prevent enteral infections.